Oncotelic Therapeutics Statistics
Want to see OTLC full AI Analyst Report?
Oncotelic Therapeutics (OTLC) Stock Statistics & Valuation Metrics
Total Valuation
Oncotelic Therapeutics has a market cap or net worth of $6.13M. The enterprise value is $33.45M.
- Market Cap
- $6.13M
- Enterprise Value
- $33.45M
Share Statistics
Oncotelic Therapeutics has 457,512,800 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 457,512,800
- Owned by Insiders
- 26.85%
- Owned by Institutions
- ―
Financial Efficiency
Oncotelic Therapeutics’s return on equity (ROE) is 0.95 and return on invested capital (ROIC) is -0.57%.
- Return on Equity (ROE)
- 0.95
- Return on Assets (ROA)
- 0.63
- Return on Invested Capital (ROIC)
- -0.57%
- Return on Capital Employed (ROCE)
- -0.01
- Revenue Per Employee
- 0
- Profits Per Employee
- 6.08M
- Employee Count
- 41
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Oncotelic Therapeutics is -0.00. Oncotelic Therapeutics’s PEG ratio is 0.00.
- PE Ratio
- -0.00
- PS Ratio
- 22.33
- PB Ratio
- 0.00
- Price to FCF
- -0.00
- Price to Operating Cash Flow
- -0.00
- PEG Ratio
- 0.00
Income Statement
In the last 12 months, Oncotelic Therapeutics had revenue of 0 and earned 249.28M in profits. Earnings per share was 0.59.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -3.19M
- Pretax Income
- 360.57M
- Net Income
- 249.28M
- EBITDA
- 361.46M
- Earnings Per Share (EPS)
- 0.59
Cash Flow
In the last 12 months, operating cash flow was -1.52M and capital expenditures -5, giving a free cash flow of -1.52M billion.
- Operating Cash Flow
- -1.52M
- Free Cash Flow
- -1.52M
- Free Cash Flow per Share
- -1698.64
Dividends & Yields
Oncotelic Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -13914450.90%
- Earnings Yield
- -19900861.05%
Stock Price Statistics
- Beta
- 0.08
- 52-Week Price Change
- -84.71%
- 50-Day Moving Average
- 0.02
- 200-Day Moving Average
- 0.04
- Relative Strength Index (RSI)
- 34.70
- Average Volume (3m)
- 391.48K
Important Dates
Oncotelic Therapeutics upcoming earnings date is Apr 19, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Aug 24, 2026
- Next Earnings Date
- Apr 19, 2027
- Ex-Dividend Date
- ―
Financial Position
Oncotelic Therapeutics as a current ratio of 0.07, with Debt / Equity ratio of 5.29%
- Current Ratio
- 0.07
- Quick Ratio
- 0.07
- Debt to Market Cap
- 0.42
- Net Debt to EBITDA
- 0.04
- Interest Coverage Ratio
- -3.60
Taxes
In the past 12 months, Oncotelic Therapeutics has paid 111.55M in taxes.
- Income Tax
- 111.55M
- Effective Tax Rate
- 0.31
Enterprise Valuation
Oncotelic Therapeutics EV to EBITDA ratio is -71.16, with an EV/FCF ratio of -21.29.
- EV to Sales
- 66126462.33
- EV to EBITDA
- -71.16
- EV to Free Cash Flow
- -21.29
- EV to Operating Cash Flow
- -21.29
Balance Sheet
Oncotelic Therapeutics has $186.01K in cash and marketable securities with $13.89M in debt, giving a net cash position of -$13.71M billion.
- Cash & Marketable Securities
- $186.01K
- Total Debt
- $13.89M
- Net Cash
- -$13.71M
- Net Cash Per Share
- -$0.03
- Tangible Book Value Per Share
- $0.58
Margins
Gross margin is 100.00%, with operating margin of -93072090.20%, and net profit margin of -444038583.03%.
- Gross Margin
- 100.00%
- Operating Margin
- -93072090.20%
- Pretax Margin
- -443994022.07%
- Net Profit Margin
- -444038583.03%
- EBITDA Margin
- -92925533.60%
- EBIT Margin
- 144320.60%
Scores
- Smart Score
- ―
- AI Score
- 44

